In multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival

Carina S. Debes Marun, Andrew R. Belch, and Linda M. Pilarski

Chromosomal abnormalities in plasma cells (PCs) from multiple myeloma (MM) provide a clonal signature to identify malignant cells. BM-lymphocytes from MM aspirates, defined by stringent criteria, were screened for the same chromosomal abnormalities as autologous PCs, including translocations, deletions, and amplifications. For 200 MM patients, we evaluated BM mononuclear cells to identify lymphocytes and autologous PCs on the same slide, followed by interphase fluorescence in situ hybridization to characterize their chromosomal abnormalities. Of all patients having a given chromosomal abnormality(ies) in PCs, 45% showed that same abnormality(ies) in 2–37% (median = 5%) of BM-lymphocytes. Most translocations, amplifications, and deletions found in MM PCs were also detected in lymphocytes, above the healthy-donor “cut-off.” In patients having chromosomally abnormal CD20+ PCs, chromosomally abnormal lymphocytes were found among CD20+ cells confirming them as B cells. Exceptions were amplification of 1q21 or p53 deletion, which characterize PCs but were undetectable in BM-lymphocytes, suggesting that processes leading to these abnormalities may be exclusive to PCs. For a set of 75 patients whose BM-lymphocytes and PCs were analyzed by all six probe sets, 58% of those with abnormal PC also had abnormal BM-lymphocytes harboring from one to five different abnormalities. Confirming the clinical significance of chromosomally abnormal BM-lymphocytes, MM patients having abnormalities in both lymphocytes and PC had significantly worse survival than those with abnormalities only in PC (HR = 2.68). The presence of at least one chromosomal abnormality in BM-lymphocytes appears to have greater clinical significance than particular abnormalities. Chromosomally abnormal BM-lymphocytes correlate with poor outcome and by extrapolation with more aggressive disease. Am. J. Hematol. 87:579–587, 2012. © 2012 Wiley Periodicals, Inc.

Introduction

Multiple genetic abnormalities have been described in multiple myeloma (MM), including numerical abnormalities and structural changes such as translocations, duplications, inversions, and amplifications. The most common numerical change is monosomy of chromosome 13 [1–5] with infrequent interstitial deletions [6,7] and trisomies of chromosomes 3, 5, 9, 11, 15, and 21 [5,6]. The most common structural abnormalities are translocations of IgH locus and amplification of 1q21 [9]. The IgH translocation partner remains unidentified in roughly 50% of MM cases having a 14q32 translocation. Several recurrent IgH translocation partners have been identified, including 11q13 (15–20%), 4p16 (5–15%), 16q23 (2–5%), 6p21 (5%), and 20q12 (2%) [10–16]. Some chromosomal abnormalities appear early in malignant development, such as the primary IgH translocations or deletion of chromosome 13, and others appear to be late acquisitions as the MM clone evolves, such as p53 deletion or 1q21 amplification [1,17]. Although no unique abnormality characterizes all MM, those harbored by the plasma cell (PC) in each patient represent clonotypic markers to identify clonal relationships within that MM patient. Although PCs mediate the pathology of MM, a substantial body of evidence indicates that the malignant clone also includes B lymphocytes that share the clonotypic IgH VDJ gene rearrangement characterizing autologous PC [18–25]. The MM clone includes not only PCs but also late-stage B cells [21] and preswitch B cells [22–25]. MM B lymphocytes are DNA aneuploid [19], have autocrine cytokine networks [26], and may mediate malignant spread [27]. Clonogenic population that are phenotypically and physically distinct from PCs include presumptive MM cancer stem cells (CSCs) [28,29]. CD20+ clonotypic lymphocytes from 3D culture of ex vivo MM BM are self-renewing and after serial passages give rise to PCs [30], as expected for CSC. Furthermore, population that include B lymphocytes but not PC xenograft human MM to immunodeficient mice [22,31,32], as do progenitor population that lack B-cell markers [33]. This suggests that MM CSC may include multiple compartments of clonotypic cells at presumptively sequential stages of differentiation with different generative capability [34].

Chromosomal abnormalities in PCs provide one or more clonotypic marker(s) distinct from the IgH VDJ rearrangement. Most studies analyze only purified PCs, excluding all other components of the MM clone. Using stringent criteria, we here analyzed BM-lymphocytes from 200 MM patients for chromosomal abnormalities that characterize autologous PCs. This strategy ensures that the chromosomal abnormalities in lymphocytes and PCs are evaluated on the same slide, with identical staining conditions, with adjacent nonmalignant cells serving as internal controls. About 15% of MM patients have CD20+ PC. After selecting patients whose clonal PCs were reported CD20−, we found that at least some of the chromosomally abnormal lymphocytes were CD20− B cells. However, the MM clone is heterogeneous, and MM CSC capability may be multifactorial [34].
of lymphocytes instead of purified B-cells enabled inclusion of most B-cell subsets, while avoiding assumptions about the nature of MM CSC. Purification of B-cells would inappropriately exclude cells that have lymphocyte morphology but lack B-cell markers as well as any dedifferentiated PC having lymphocyte morphology. The validity of this strategy is verified by our observation that chromosomally abnormal BM-lymphocytes correlate with significantly reduced survival, independent of treatment(s) or type of abnormality.

Materials and Methods

Patients. BM samples were collected from 200 randomly selected MM patients (Table I) in accord with the Declaration of Helsinki, with the approval of Institutional Review Boards of the University of Alberta and Alberta Health Services and written informed consent. For 175 patients, the samples analyzed by fluorescence in situ hybridization (FISH) were pretreatment diagnostic BM. For 25 patients, BM aspirates were taken during or after treatment; 11 of these patients were in relapse and 14 were on treatment, including VAD, lenalidomide, bortezomib, and dexamethasone in different treatment protocols.

Cytomorphology and FISH. Cytospin slides were prepared from the BM mononuclear cells obtained by density gradient centrifugation (Ficoll–Hypaque) as previously described [19], followed by May Grünwald–Giemsa staining (MGG) [35,36]. Using the Biovie Duet (Rehovot, Israel), automated scanning of each slide identified the lymphocytes and PCs, based solely on morphology, and their positions on the slide, verified by visual inspection, were recorded. Monocytes (M) and/or polymorphonuclear (PMN) cells on the same slide served as internal negative controls. Lymphocytes were evaluated on the same slide as the positive (PC) and negative control (e.g., PMN) population, thereby ensuring identical staining conditions for test and control-cell slide as the positive (PC) and negative control (e.g., PMN) population, serving as internal negative controls. Lymphocytes were evaluated on the same slide, verified by visual inspection, were recorded. Monocytes (M) and/or polymorphonuclear (PMN) cells on the same slide served as internal negative controls. Lymphocytes were evaluated on the same slide as the positive (PC) and negative control (e.g., PMN) population, thereby ensuring identical staining conditions for test and control-cell types. MGG was then destained using ice-cold methanol-acetic acid (3:1) as previously described [35,36].

Stringent criteria were used to define lymphocytes: cell size between 7 and 12 μm, high nucleus to cytoplasm ratio (N/C ratio), nucleus oval or slightly indented, dense clumped homogenous chromatin devoid of nucleoli, little rough endoplasmic reticulum (RER) light blue basophilic cytoplasm from scanty to medium, mostly agranular, but including large granular lymphocytes. These criteria exclude PCs, plasmablasts, and lymphoplasmodomal cells by their smaller N/C ratio, much denser and patchy chromatin condensation, increased cytoplasm and cytoplasmic basophilia, and increased amounts of RER that define the characteristics of the perinuclear zone. Monocytes are excluded by their smaller N/C ratio, nonhomogeneous chromatin, larger size, indented nucleolus, and gray, less basophilic cytoplasm with dusty granulation. Blasts were excluded by their higher N/C ratio, immature open chromatin, higher cytoplasmic basophilia and presence of nucleolus, and sometimes large blastic. The criteria also exclude all granulocyte and red-cell precursors. None of the patients with abnormalities in their lymphocytes had “small lymphocyte-like” PC myeloma [37], and only two were reported to have lymphoplasmodomal morphology.

Fluorescence in situ hybridization (FISH) was performed to detect the most common genetic abnormalities present in MM patients. Probes were from Vysis (Abbot Molecular) through Intermedico (Ontario, Canada) unless otherwise noted. D13S319 was used to detect the deletion of chromosome 13 (13 probe), a mixture of LSI p53 and D17Z1 (CEP17, centromeric probe) to detect p53 deletion (p53 probe), LSI 1q21 (red color break apart probe) to detect amplification of the IgH locus (BA probe), LSI IgH/CCND1-XT DF to detect translocation t(11;14)(q13;q32) (11;14 probe), and LSI IgH/FGFR3-FISH DF to detect translocation t(4;14)(p16;q23) (4;14 probe). To detect amplification of the t(4;14) locus that includes the C-KS-18 gene, probes were provided by Dr. John Shaughnessy [17] to test the first 20 patients. We then developed our own probe of DNA from SAC-dox-RPDR11-307C12 labeled with a Vysis kit, coupled with a commercial λ-satellite probe targeting centromere of chromosome 1 (D1Z5) (ch1 probe); the remaining patients were assessed using this latter set of probes. Both probes gave similar results. FISH was performed as previously reported with minor changes [36]. Published protocols were used for the t(4;14) probe provided by Dr. Shaughnessy [17]. Overall, for the first 100 patients, PC and lymphocytes were assessed on the same slide regardless of the presence or absence of abnormalities. For the following 100 patients, the lymphocytes were assessed only if autologous PCs on the same slide were found to have chromosomal abnormalities.

To categorically identify B lymphocytes but avoid morphological changes that accompany staining and sorting, for seven randomly selected patients, cytopsin slides were immunostained with anti-CD20 to identify the lymphocytes harboring chromosomal abnormalities using dual-color FISH (Daco CD20) from Daco polyclonal against mouse antibody (Dako envision system), and AEC (3-amino-9-ethylcarbazol) for color development (Dako) as per manufacturer’s instructions. We recorded the location of the CD20+ cells and performed FISH as previously described. We also performed FIC-TION (fluorescent immunophenotyping and in situ cytogenetics) on five selected patients (different from the immunostained ones) using L26, detected with Marine Blue antinouse Molecule Probes-Invitrogen Canada, Burlington, ON), fixation in 2% paraformaldehyde for 5 min at RT and FISH as described earlier. These methods are complex but confirm that at least a proportion of abnormal lymphocytes are B cells.

For all FISH-stained slides, normal hematopoietic cells (e.g., M and L) were analyzed on each slide to search for presumptive “false-positive” cells. The cut-off percentages for each probe were established to be 4% for the deletion of p53, 8% for the amplification of 1q21, 5% for the IgH break apart probe, and 2% for the remainder of the probes. For the dual-fusion probe, 1% was set as an arbitrary cut off, because no false positives were detected for either probe set in healthy lymphocytes. As previously reported, about 40% of the patients with MM have hyperdiploidy and 22% hypodiploidy [5,8]. When using any of the probes described earlier, amplifications or deletions of the specific chromosomal region are also detected. Although these abnormalities are not the ones that the probe was intended to detect, they are still clonal markers for the MM PC; therefore, lymphocytes showing the same pattern of abnormality as autologous PCs were also considered to be clonal. To decide if an alternative locus abnormality was significant (e.g., amplification of chromosome 4 detected with the 4;14 probe), we averaged the false positives detected in the lymphocytes of healthy donors and established a common cut off. Any chromosomal deletion was significant if detected in more than 4% of the lymphocytes, and any chromosomal amplification was significant if detected in more than 3% of lymphocytes. For the PC analysis, we followed the European Myeloma Network guidelines [38]. For all FISH-stained slides, normal hematopoietic cells (e.g., M and PMN) in the BM were screened as internal controls for the abnormalities detected by a given probe set. These were always below the designated cut off.

American Journal of Hematology

"research article"

**TABLE I. Clinical Parameters of MM Patients**

| Parameter          | Median (Range) |
|--------------------|----------------|
| Age (median)       | 64 (33-90)     |
| Sex (male %)       | 61.5           |
| Isotype (%)        | 3.5            |
| IgG                | 61.8           |
| IgA                | 21.5           |
| LC                 | 10.2           |
| Other/unknown (%)  | 5.2            |
| light chain (K %)  | 60             |
| % BM plasmacytoid | 40 (2-100)     |
| mg/L j2 microglobulin | 4.2 (1.44-113) |
| g/D Urine LC median (range) | 0.39 (0.5-1.9) |
| g/l Albumine median (range) | 43 (21-77) |
| U/L LDH median (range) | 441 (213-1908) |
| g/l Hemoglobin median (range) | 113 (72-171) |
| μmol/L Creatinine median (range) | 99 (45-959) |
| mmol/L Calcium median (range) | 2.36 (1.63-3.83) |

IgG, immunoglobulin G; IgA, immunoglobulin A; LC, light chain; BM, bone marrow; M, mononuclear; LDH, lactate dehydrogenase.

580
BM slides from 200 MM patients were separately stained with one or more different probes or probe sets; most were stained only with some of the indicated probes. BM slides from a subset of 75 patients were separately stained with all probe sets (see Results and Figure 4). One hundred and thirty-five patients had at least one detectable abnormality with the probe sets used. Amplification of the locus was more than two copies; deletion of the locus was less than two copies; any abnormality was all the abnormalities that could be detected by the probe including translocations, amplifications, and deletions. For six patients with amplification of at least three of the tested chromosomes (1, 4, 11, 14, and 17), although in PC, we detected two signals for chromosome 13, we still considered them as having a deletion following the European Myeloma Network guidelines [39]. Interestingly, three of these six patients have 6–8% of their BM-lymphocytes harboring three signals for ch13, suggesting that loss of the third ch13 occurred only in the PC population.

As determined by a centromeric-specific probe (see Methods section).

### Results

#### Experimental approach

We analyzed PCs and lymphocytes in BM from 200 consecutive MM patients: 169 for the BA probe, 101 for chromosome 13, 127 for t(4;14)(p16;q32), and 117 for t(11;14)(q13;q32). BM was analyzed from 80 patients for chromosome 17 (p53) and from 78 patients for chromosome 1, as summarized in Table II/Fig. 1. Lymphocytes were identified by stringent morphologic criteria that would include, for example, T, NK, B cells, lymphocytic MM cells lacking B-cell markers, and any “dedifferentiated” PC with lymphocyte-like morphology. MM-related lymphocytes harboring chromosomal abnormalities are expected to comprise only a portion of total BM-lymphocytes. For a subset of patients, immunostaining or immunofluorescence with CD20 preceded FISH: in most cases, abnormal cells expressing CD20 were seen, but non-CD20 cells with abnormalities were also detected. Analyzing lymphocytes, PCs and negative control cells on the same slide, in identical staining conditions, provides rigorous internal controls but likely underestimates the true frequency of chromosomally abnormal lymphocytes.

For BM PCs, the incidence of abnormalities was as expected. In PCs, we detected deletion 13 in 42.5% of the patients, 1q21 amplification in 35%, p53 deletion in 9%, t(4;14)(p16;q32) in 12%, t(11;14)(q13;q32) in 21%, and any translocation of 14q32 in 47% of the patients. In a set of 75 patients from whom we had sufficient BM to assess staining with all probe sets in parallel, 93% had PCs with at

| Probe | Detected pattern using the probe | % of patients with abnormality in PC | % of (+) patients whose BM lymphocytes have the same abnormality as PC | % of lymphocytes with abnormality. Median (range) |
|-------|----------------------------------|--------------------------------------|---------------------------------------------------------------------|--------------------------------------------------|
| BA    | any IgH translocation            | 47%                                  | 23%                                                                 | 16% (13-20%)                                     |
|       | amplification 14q32              | 14%                                  | 9%                                                                  | 4%                                               |
|       | deletion 14q32                   | 10%                                  | 18%                                                                 | 9% (5-37%)                                       |
|       | any abnormality                  | 55%                                  | 20%                                                                 |                                                  |
| (4;14)| t(4;14) translocation            | 12%                                  | 30%                                                                 | 3% (2-6%)                                        |
|       | amplification 4p16               | 5.5%                                 | 57%                                                                 | 6% (4-11%)                                       |
|       | amplification 14q32              | 20.5%                                | 50%                                                                 | 9% (4-18%)                                       |
|       | deletion 14q32                   | 12%                                  | 20%                                                                 | 12% (5-19%)                                      |
|       | amplification 4p16 plus amplification 14q32 | 5.5% | 71% | 8% (4-13%) |
|       | any abnormality                  | 50%                                  | 47%                                                                 |                                                  |
|       | (11;14) | translocation                  | 21% | 23% | 5% (2-20%) |
|       | amplification 11q23              | 26%                                  | 19%                                                                 | 8% (4-15%)                                       |
|       | amplification14q32               | 12%                                  | 50%                                                                 | 7% (4-17%)                                       |
|       | deletion 14q32                   | 5%                                   | 33%                                                                 | 16% (5-27%)                                      |
|       | amplification 11q23 plus amplification14q32 | 12% | 25% | 7.5% (4-15%) |
|       | any abnormality                  | 72%                                  | 32%                                                                 |                                                  |
| 13q14 | deletion 13                      | 42.5%                                | 25.5%                                                               | 7.7% (6-30%)                                     |
|       | trisomy                          | 3%                                   | 66%                                                                 | 12.5% (8-17%)                                    |
| p53   | deletion p53                     | 9%                                   | 0%                                                                  |                                                  |
|       | trisomy 17                       | 11%                                  | 33%                                                                 | 4% (4-5%)                                        |
| 1q21  | amplification locus              | 35%                                  | 0%                                                                  |                                                  |
|       | trisomy                          | 20.50%                               | 31%                                                                 | 6% (4-34%)                                       |
|       | monosomy                         | 2.5%                                 | 0%                                                                  |                                                  |

BM slides from 200 MM patients were separately stained with one or more different probes or probe sets; most were stained only with some of the indicated probes. BM slides from a subset of 75 patients were separately stained with all probe sets (see Results and Figure 4). One hundred and thirty-five patients had at least one detectable abnormality with the probe sets used. Amplification of the locus was more than two copies; deletion of the locus was less than two copies; any abnormality was all the abnormalities that could be detected by the probe including translocations, amplifications, and deletions. For six patients with amplification of at least three of the tested chromosomes (1, 4, 11, 14, and 17), although in PC, we detected two signals for chromosome 13, we still considered them as having a deletion following the European Myeloma Network guidelines [39]. Interestingly, three of these six patients have 6–8% of their BM-lymphocytes harboring three signals for ch13, suggesting that loss of the third ch13 occurred only in the PC population.
least one abnormality and 58% of those patients had at least one abnormality shared between PCs and lymphocytes.

Results from a given slide were included in the analysis only if identified abnormalities were below the designated cut off for autologous BM M/PMN cells on the same slide (internal negative control). Overall, BM M/PMN was always below cut off for abnormalities.

Translocation probes

To assess for translocations of 14q32, we used a BA probe (‘break apart’) that detects any translocations on 14q32, a dual-fusion t(4;14) probe, and a dual-fusion t(11;14) probe. The dual-fusion probes detect two different chromosomal regions, one in 14 and one in 4 or 11, respectively, so that amplifications (amp.) or deletions (del.) in either locus were recorded. For example, a patient having trisomy 11 will show amplification for the 11q13 probe, which we designate as amp11. The abnormalities detected in BM-lymphocytes are summarized in Table II. Figure 2 demonstrates lymphocytes with genetic abnormalities. Figure 3 shows that for a subset of patients whose BM cells were stained with CD20, some abnormal lymphocytes were CD20+.

For unbalanced translocations (25% of the translocations detected by the 4;14 or 11;14 probe sets), we were usually unable to report lymphocytes with the same translocation. This is because an observed pattern of 1F1G1R is frequently regarded as overlapping signals unless the percentage of cells presenting this pattern is above 20%. Nevertheless, we were able to detect this pattern in 3 of 14 patients, affecting 19–29% of BM-lymphocytes.

BA probe

The BA probe was used for BM from 169 patients, identifying an IgH translocation in 79 patients (47%), in 14–100% of PCs (median = 78%). For 18 (23%) of those patients presenting the abnormality in PCs, we found the same abnormality in the BM lymphocytes. One 14q32 was deleted in the PCs of 17 (10%) of the patients, with the same abnormality in the lymphocytes from three (18%) of them. Likewise, amplification of the 14q32 was detected in 23 (14%) patients with BM-lymphocytes bearing the same abnormality in two (9%) of them. In nine patients, this probe was not informative. Taking into account all the abnormalities detectable with the BA probe, at least one was seen in PCs from 55% of the patients and the same abnormality in BM-lymphocytes from 20% of them.

$t(4;14)$

BM from 127 patients was assessed. Overall, patients having $t(4;14)$ comprised 25% of BA positive patients and 12% of the total cohort. Twenty patients had $t(4;14)$ in 18–96% of PCs (median = 88%) with 6 (30%) of them also having the abnormality in 2–6% of the BM-lymphocytes (median = 3%). Twenty-six patients (20.5%) showed amplification of ch14 and seven (5.5%) amplification of ch4 in PCs, with BM-lymphocytes also bearing the same abnormalities in 50 and 57%, respectively, of the same set of patients. There were 7 (5.5%) patients that had amplification of both loci in the same PCs, and 5 (71%) of them had dual amplification in the lymphocytes as well.

For deletions, one patient had only one copy of ch4 in PCs (also shown in the lymphocytes) but 15 (12%) with only one signal for ch14. Del14 was detected in the lymphocytes from three (23%) patients with del14 in BM-PC. Taking into account all abnormalities detected by this probe (translocations, amplifications, and deletions), we detected at least one abnormality in PC from 50% of the patients studied, with 47% of the same patients having identical abnormalities in their BM-lymphocytes (Fig 2). Some abnormal cells were CD20+ (Fig 3).

$t(11;14)$

Thirty-five patients (44% of BA positive patients and 21% of all patients studied) have detectable translocation (11;14) in their BM-PC, with 30–100% of positive PC (median = 79%). The same abnormality was observed in 2–7% of the BM-lymphocytes (median = 5%) in eight of those translocated patients (23%). Amplification of 11q23 was detected in BM-PC from 31 patients (26%), 6 of whom also had amp11 in 4–15% of BM-lymphocytes. Amp14 was detected in 14 patients (12%) with 4–17% of the lymphocytes having the same aberration in seven of those patients (50%). We also found 14 patients (12%) with PCs having both amp11 and amp14;
25% of these patients had BM-lymphocytes harboring the same dual amplifications. We found del14 in six patients and of those, two (33%) show the same abnormality in their BM-lymphocytes.

Considering all of the abnormalities that can be detected with this probe, at least one abnormality was found in 72% of the patients tested, and for 32% of these patients, the same abnormality was found in the BM-lymphocytes (Fig. 2), including some that were CD20+ (from patients whose PCs were CD20−; Fig. 3).

Deletion-amplification probes

We used three probes to detect deletions or amplification. To assess for the deletion of chromosome 13, we used D13S319 (regarded to be the most commonly deleted region in some studies [38]). A combination of a centromeric probe and a locus-specific probe was used to assess for p53 deletion and amplification of 1q21. Results are summarized in Table II.

Deletion 13 (del13)

When del13 is detected, in most cases, this represents monosomy [15,40]; in only a minority of cases does this represent an interstitial deletion. Hence we chose to utilize only one probe to assess for this abnormality. BM from 101 patients was analyzed. About 42.5% of patients showed del13 in 13–99% of BM-PC (median = 78%), and 11 (25.5%) of them also have the same abnormality in BM-lymphocytes (6–30%, median = 7%).

In three patients, we found amp13 in BM-PC (11–30% of PC). For two of these patients, amp13 was also detected in 8 and 17% of their BM-lymphocytes.

Overall, of 46% patients with ch13 abnormalities in PCs, 28% had the same abnormalities in their BM-lymphocytes (Fig. 2), including CD20+ cells (Fig. 3).

Deletion of p53

We studied 80 patients and identified delp53 in seven patients (9%) in 43–98% of PC (median = 80%). We were unable to detect lymphocytes harboring delp53 for any of these patients. However, we did find nine patients (11%) showing trisomy 17 (detected by the centromere17 probe) and found the abnormality in 4–5% of the BM-lymphocytes in three of them (33%). This indicates that abnormal lymphocytes were present in the BM but did not acquire delp53, suggesting that delp53 may be generated by events that occur only in PC.

Amplification of 1q21

Among 78 patients tested, amp1q21 was detected in 27 (35%) patients in 12–99% of PC (median = 77.5%). As was the case for delp53, we were unable to detect lymphocytes harboring amp1q21 above the cut-off threshold. In addition, two patients presented with monosomy 1 (detected by centromeric probe) in their PC, but the abnormality was not detected in their lymphocytes.

In contrast, 15 patients (19%) had PC with trisomy 1 and 1 patient had tetrasomy 1. For five of these patients (31%), we found the same abnormalities in their BM-lymphocytes. This indicates that BM-lymphocytes with ch1 abnormalities were present in BM of the affected patients, but they did not acquire amp1q21 or del1, suggesting that amp1q21 and del1 may be generated by events restricted to PC.

Abnormal BM-lymphocytes are more frequent in patients whose PCs harbor multiple abnormalities

In a cohort of 75 patients, each tested for all probe sets, we determined the extent to which detection of abnormal BM-lymphocytes was dependent on the number of abnormalities found in autologous PCs (Fig. 4). For this cohort of 75, 93% had at least one abnormality in their BM-lymphocytes (Fig. 4). We used the probe sets indicated earlier. Ten patients (13%) had only one abnormality in their PCs, and for these, BM-lymphocytes had the same abnormality in three of them (30%). Eleven patients (15%) had two abnormalities in their PCs, but the BM-lymphocytes from five of them had only one abnormality (45%). There were 17 (23%) patients with three abnormalities, and the same abnormalities were detected in BM-lymphocytes for 76% of them; 53% of these had one abnormality in the lymphocytes, 17% had two abnormalities in the lymphocytes, and 6% had three abnormalities in the lymphocytes. Eight patients (10%) had four abnormalities in their PCs; two abnormalities were detected in the BM-lymphocytes for 50% of them. There
were 14 (19%) patients with five abnormalities in their PCs; the same abnormalities were detected in the BM-lymphocytes from 71% of them: 21% had one abnormality in BM-lymphocytes, 29% had two abnormalities, and 21% had three abnormalities. For those patients presenting with six abnormalities in their PCs (7%), we found one abnormality in BM-lymphocytes in 17%, two abnormalities in 33%, three abnormalities in 17%, and four abnormalities in 17%, totaling 83% of these patients having abnormal BM lymphocytes. There were only three patients, in whom we detected seven abnormalities in the PC, and of those one patient had one abnormality in their lymphocytes and a second had two abnormalities in their lymphocytes.

Overall, based on analysis of all six probe sets, 70 of 75 patients (93%) had at least one abnormality in their BM-PC and of these 58% had at least one abnormality present in their BM-lymphocytes.

The presence of chromosomal abnormalities in BM-lymphocytes correlates with significantly reduced overall survival

First, we compared all 200 patients, whether or not they had chromosomal abnormalities in their PCs, with each subset of patients who had at least one abnormality their BM-lymphocytes (each abnormality separately). Those patients having deletion 13 or t(4;14) in their BM-lymphocytes have a significantly shorter overall survival (OS) than patients without either of these abnormalities in BM-lymphocytes ($P = 0.01, HR = 2.40$ for del13; $P = 0.0001, HR = 5.36$ for t(4;14); Fig. 5, panel A).

We then compared the OS of patients that have abnormalities only in PC with a second group having abnormalities in both PC and BM-lymphocytes. We find that patients with abnormalities present in both PC and BM-lymphocytes had a significantly worse OS than those patients with abnormalities present only in PC ($P = 0.01, HR = 2.68$; Fig. 5, panel C), regardless of the abnormality detected.

Discussion

Using stringent morphologic criteria to define lymphocytes and PC, we show here that for all analyzed MM patients having at least one chromosomal abnormality in their PCs, 45% also have at least one such abnormality in their BM-lymphocytes, shown for a subset of patients to include CD20+ cells. This approach avoids any need to make assumptions about the phenotypes comprising the MM clone, given that purification of B-cells potentially excludes important sets of CSC. We screened BM-lymphocytes for IgH translocations, deletions/amplifications, and numerical abnormalities and identified a total of 17 different numerical or structural abnormalities in PC, nearly all of which were also detected in BM-lymphocytes of at least some patients. Furthermore, analysis of OS revealed that patients who had at least one chromosomal abnormality in both BM-lymphocytes and PC had significantly worse survival than did those patients having abnormalities only in their PCs. When all 200 patients were included in the analysis, regardless of the chromosomal status of their PCs, patients with at least one abnormality in their BM-lymphocytes still showed significantly worse survival independent of treatment type(s). Based on individual chromosomal abnormalities, only del13, translocation t(4;14), and trisomy1 showed a correlation with OS. The presence of chromosomal abnormalities in BM-lymphocytes provides strong evidence for their participation in the malignant process in MM, perhaps as CSC, as well as a marker for their identification. The presence or absence of any particular chromosomal abnormality may be of less clinical significance than the fact that abnormal lymphocytes populate the BM, and their presence correlates with reduced survival.

For the most part, BM-lymphocytes had only one abnormality, always reflecting the same abnormality in PC from the same slide, but for some patients as many as four distinct abnormalities were detected in their BM-lymphocytes, all shared with autologous PC. BM-lymphocytes comprise multiple subsets with specific shared morphologic characteristics, but only some (from 2 to 37%) are shown to be MM-related lymphocytes. Overall, numerical abnormalities, especially hyperdiploidy, were the most frequent among BM-lymphocytes (9–71%) in terms of the number of patients involved. IgH translocations were frequent (23–30% of patients) but usually comprised a smaller proportion of lymphocytes (2–20%) in any given patient. Del13 was frequent (25.5% of patients, in 6–30% of lymphocytes), but del17, translocation t(4;14), and trisomy1 showed a correlation with OS. Del17 was frequent (31–33% of patients). Among lymphocytes, numerical abnormalities in ch1 and ch17 indicate that aberrant events, likely during mitosis, do affect ch1 and ch17, but are diverted from the deletion and amplification events that lead to del17(p53) and amp1q21. Our work suggests that these latter abnormalities, amp1q21 and del17(p53), are generated only in PC, consistent with their categorization by others as progression events during MM evolution [41–43]. In lymphocytes, among the abnormalities detected are those thought to be early stage biomarkers for MM (IgH

![Graph showing percentage of patients with different numbers of abnormalities](image-url)
translocations, hyperdiploidy, and del13), some of which are found in MGUS [1,43,44].

A BM aspirate includes white blood cells physically present at a defined geographical location in the body. Thus, BM-lymphocytes were in relatively close proximity to their presumed progeny, the BM-PC. Analysis of BM architecture shows localized clusters of lymphocytes adjacent to PC, suggesting a lineage relationship [44,45], supported by 3D

Figure 5. The presence of chromosomally abnormal BM-lymphocytes correlates with reduced survival. Panel A: Aggregate overall survival (OS) analysis of all 200 patients analyzed, comparing those patients having deletion 13 (P = 0.01) or translocation 4;14 (P = 0.0001) in their BM-lymphocytes with those lacking these abnormalities. The survival comparison also showed a trend toward reduced survival for patients having BA positive, trisomy1, and deletion of 14q32 (with 4;14 probe) (P = 0.08).

Panel B: OS analysis comparing patients having the indicated abnormality only in their PC with patients having the same abnormality in both PC and lymphocytes (statistically significant only for deletion 13 (P = 0.002), trisomy 1 (P = 0.001), with a trend for t(4;14) (P = 0.08).

Panel C: Aggregate OS analysis of 135 patients who had at least one abnormality in their PC, comparing patients having any abnormality present only in the PC with patients having any abnormality in both PC and lymphocytes (P = 0.01). Correlation between abnormal BM-lymphocytes and other clinical parameters: Univariate analysis showed that if deletion 13 was present in the lymphocytes, then the OR of having light chain (LC) present in urine versus not having light chain is 3.17, with 95% confidence interval (CI). Likewise, the OR of having higher levels of creatinine versus lower levels of creatinine is 5.07, 95% CI, if the patient harbors del13 in BM lymphocytes. In contrast, the presence of trisomy 17 in the lymphocytes inversely correlated with a higher amount of B2 microglobulin OR: 0.03, 95% CI. These correlations remained significant in the multivariate analysis. The presence of multiple abnormalities in PC and/or lymphocytes did not add any significance to the above correlations.
culture model within which self-renewing CD20+ clonotypic lymphocytes from BM ultimately gave rise to PC [44], as expected for putative CSC. Although we and others [35,46,47] have described clonotypic B cells in the circulation of MM patients, and chromosomal abnormalities have been detected in circulating MM B cells, there have been few reports characterizing BM-lymphocytes with respect to clonal characteristics shared with MM-PC. Our observation that lymphocytes and PCs in the same aspirate share chromosomal abnormalities provide evidence for a lineage relationship between these two compartments of the MM clone, suggesting that many chromosomal abnormalities may arise in lymphocytes and are passed to their PC progeny or the unlikely possibility that a subset of MM-PC reverts to lymphocyte morphology. This latter possibility seems excluded by the absence of deletion p53 and amp1q21 in BM-lymphocytes. The absence of del17(p53) and amp1q21 from BM-lymphocytes suggests that at some point, the PC compartment of the MM clone becomes self-sustaining, giving rise to clonal expansions harboring markers not found in BM-lymphocytes.

Of 135 patients with at least one abnormality in their PC, 45% (61) also had at least one abnormality in their BM-lymphocytes. This is almost certainly an underestimate of the frequency with which lymphocyte abnormalities are present, because the test only detects abnormal cells rising above a threshold or cut-off value for that probe set. The cutoff represents the number of “false positives” among healthy lymphocytes and is heavily dependent upon the probes used. Internal controls on each slide validated the analysis of BM-lymphocytes, with autologous PC providing the positive control and autologous M/PMNs providing negative control populations on the same slide and ensuring specificity of the testing. BM includes ~11–24% lymphocytes, many unrelated to the MM clone. Moreover, if the number of clonotypic aberrant B cells is below the test threshold, they will remain undetectable, even though they may have bona fide chromosomal abnormalities. Our results are informative but likely to underestimate the true incidence of chromosomally abnormal BM-lymphocytes.

For a subset of 75 patients, we tested all probes to evaluate both PCs and BM-lymphocytes. In this set, 58% of patients with at least one abnormality also had the same abnormality(s) in their BM-lymphocytes. PCs had from only one to as many as four distinct chromosomal abnormalities. Autologous lymphocytes had as many as four distinct abnormalities. The more abnormalities that are present in the PCs, the greater the likelihood of detecting at least one abnormality in the BM-lymphocytes. For patients with more than one chromosomal abnormality in their PCs, about half also had more than one abnormality in their BM-lymphocytes.

Some patients had PCs bearing four to seven signals for chromosome 11, but the maximum among their BM-lymphocytes was three signals for ch11 (except one case with four). This suggests that the extent of mitotic dysregulation required to gain four to seven copies of ch11 may occur only in PCs and by extension only at later stages of disease. A variety of evidence suggests that PCs eventually acquire some degree of replicative autonomy that no longer involves lymphocytes. In this context, it is relevant that PCs express high levels of RHAMM, an oncogene that binds to the centrosome and mediates instability of the mitotic spindle [48] leading to lagging chromosomes and chromosomal missegregation [49]. RHAMM-mediated chromosomal abnormalities may eventually contribute to the outgrowth of chromosomally abnormal PCs that are likely to have only limited generative potential [39].

Given the compelling evidence that lymphocytes comprise a clinically important compartment of the MM clone and may include CSC, we suggest that in overt MM, clonal expansion may simultaneously occur on at least two levels, first that of the B cells, which persistently give rise to PC, and second that of PC themselves as they continue clonal expansion in the absence of contributions from the B cells. Abnormalities such as del13, hyperdiploidy, or IgH translocations may characterize initial clonal expansion of MM, maintained by clonotypic and chromosomally abnormal lymphocytes with extended generative potential [39], which may be MM CSC, while del17(p53) or amplification of 1q21 may occur as progression events restricted to PC. Furthermore, the presence of abnormalities in the lymphocyte compartment confers an unfavorable prognosis for affected patients, either because is reflective of a more aggressive disease and/or because this compartment represents a drug-resistant reservoir of CSC that maintains the disease. The presence of chromosomally abnormal BM-lymphocytes confirms their intimate clonal relationship with MM PC and supports the idea that MM lymphocytes are key contributors throughout malignant progression.

Acknowledgments
We especially thank George Zhu for the statistical analysis and Lina Robayo for helping with sample processing and data collection. We thank Eva Baignorri, Amanda Warke, and Sarah Motz for excellent technical assistance.

Author Contributions
CSD designed and performed the experiments, collected, reported, analyzed, and interpreted the data, prepared tables and figures, and wrote the manuscript. LMP supervised the work, designed the experiments, analyzed and interpreted data, and wrote the manuscript. ARB analyzed and interpreted the data, provided samples, and wrote the manuscript.

References
1. Aret-Loiseau H, Li JY, Godon C, et al. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol 1999;106:717–719.
2. Perez-Simon JA, Garcia-Sanz R, Taberner MD, et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood 1998;91:3366–3371.
3. Zojer N, Kingsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000;95:1925–1930.
4. Facon T, Aret-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566–1571.
5. Forseca R, Barlogie B, Bataille R, et al. Genetics and cytogenticities of multiple myeloma: A workshop report. Can Res 2004;64:1546–1558.
6. Aret-Loiseau H, Daviet A, Saunier S, Bataille R, Integroupe Francophone du Myelome. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 2000;111:1116–1117.
7. Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2006:96:1505–1511.
8. Debès Manon C, Dewald G, Bryant S, et al. Chromosome abnormalities clustering and its implications for the pathogenesis and prognosis in myeloma. Leukemia 2003;17:427–436.
9. Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27kip1 and an aggressive clinical course in multiple myeloma. Hematologica 2005;10 (Suppl 1):117–126.
10. Loiseau HA, Fancon T, Grosbis B, et al. Oncogenesis of multiple myeloma 1q43 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features and clinical presentation. Blood 2002;99:2185–2191.
11. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260–264.
12. Chesi M, Bergsgaard PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q21 by translocation to an Ig locus in multiple myeloma. Blood 1998;91:4457–4463.
13. Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t(4;11)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997;90:4062–4070.
14. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003;101:1520–1529.

15. Ho PJ. Chromosomal and genetic abnormalities in myeloma. Clin Lab Haematol 2002;24:259–269.

16. Sawyer JR, Lukacs JL, Thomas EL, et al. Multicolour spectral karyotyping identifies near-triploidy in malignant primary myeloma cells: A potential tool for chromosome loss in multiple myeloma. Br J Haematol 2001;112:167–174.

17. Chng WJ, Giebok O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007;4:571–596.

18. Szczepke AJ, Seeberger K, Wizniak J, et al. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 1999;92:2844–2855.

19. Pilarski LM, Giannakopoulos NV, Szczepke AJ, et al. In multiple myeloma, circulating hyperdiploid B cells have clonotrophic immunoglobulin heavy chain rearrangements and may mediate spread of disease. Clin Cancer Res 2000;6:585–598.

20. Baikus M, Van Riet I, De Greet C, et al. The clonogenic precursor cell in multiple myeloma. Leuk Lymph 1995;18:221–229.

21. Szczepke AJ, Seeberger K, Wizniak J, et al. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. Blood 1998;92:2844–2855.

22. Reiman T, Seeberger K, Taylor B, et al. Persistent pre-switch myeloma cells correlate with decreased survival: Evidence for isotype switching within the myeloma clone. Blood 2001B:2791–2799.

23. Billaudeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cells. J Exp Med 1993;178:1023–1031.

24. Corradini P, Boccadoro M, Voena C, Pileri A. Evidence for a bone marrow B cell compartment serving as the clonal reservoir for malignant plasma cell CDVJG rearrangement: Potential for autocrine and paracrine networks. Exp Hematol 2001;29:1076–1081.

25. Baikus MHC, Van Riet I, Van Camp B, Thielemans K. Evidence that the clonotypic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 1994;87:68–74.

26. Szczepke AJ, Belch AR, Pilarski LM. Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: Potential for direct cytokine action. Exp Hematol 1999;27:1076–1081.

27. Masellos-Smith A, Belch AR, Mant MJ, et al. Hyaluronan (HA)-dependent motility of B cells and leukemic plasma cells in blood but not of bone marrow plasma cells, in multiple myeloma: Alternate usage of RHAMM and CD44. Blood 1996;92:1861–1869.

28. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:2322–2336.

29. Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: Pathophysiological and clinical implications. Blood 2011;117:4409–4419.

30. Aghai E, Avni G, Lurie M, et al. Bone marrow biopsy in multiple myeloma: A clinical pathological study. Israel J Med Sci 1988;24:298–301.

31. Pilarski LM, H represent G, Seeberger K, et al. Myeloma progenitors in the blood of patients with aggressive or minimal disease: Engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000;95:1056–1065.

32. Pilarski LM, Seeberger K, Coupland RW, et al. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD SCID mice. Exp Hematol 2000;28:221–229.

33. Pilarski LM, Belch AR. Clonotypic myeloma cells able to xenograft myeloma to NOD SCID mice are detectable among CD34+ hematopoietic progenitors. Clin Cancer Res 2001;7:3198–3204.

34. Kittrell J, Thielman KJ, Martin LD, et al. A unique 3-D model for evaluating the impact of therapy on multiple myeloma. Blood 2008;112:2935–2945.

35. Debies-Marun C, Belch AR, Pilarski LM. Circulating B lymphocytes from peripheral blood of multiple myeloma harbour t(4;14) translocations and chromosome 13 deletions. Blood (ASH Annual Meeting Abstracts) 2005;106:500.

36. Debies Marun C, Sieben VJ, Pilarski PM, et al. FISH and chips: Chromosomal analysis on microfluidic platform. IENanobiotechnology 2007;7:27–35.

37. Heemaekers-McKenney A, Waldron J, Hughes S, et al. Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma. A potential mimic of mature B-cell lymphoma. Am J Clin Pathol 2010;133:265–270.

38. http://www.cytogenetics.org.uk/profstandards/myeloma.htm. Accessed Sep 7, 2006.

39. Pilarski LM, Reiman T, Pilarski PM, et al. The malignant hierarchy in multiple myeloma: Relationships between malignant cells and bone disease. In: Singh G, Or FW, editors. Bone Metastasis and Molecular Mechanisms Pathophysiology. The Netherlands: Kluwer; 2004. pp. 109–138.

40. Eleneaei MO, Harroudi RA, Swansbury J, et al. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer 2003;36:99–106.

41. Fonseca R, Bergsagel PL, Drach J, et al. International myeloma working group molecular classification of multiple myeloma: Spotlight review. Leukemia 2009;23:2210–2221.

42. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108:1724–1734.

43. Decaux O, Lode L, Minvielle S, Avet-Loiseau H. Genetic abnormalities in multiple myeloma: Role in oncogenesis and impact on survival. Rev Med Interne 2007;28:677–681.

44. Bochtler T, Hegenbarth U, Cremer FW. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood 2008;111:4700–4705.

45. Bartl R, Frisch B, Dierm H, et al. Bone marrow histology and serum beta 2 microglobulin in multiple myeloma—A new prognostic strategy. Eur J Haematol 1989;43:89–94.

46. Nilsson T, Nilsson L, Lenhoff S, et al. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: Evidence for frequent de novo occurrence and multipotential stem cell involvement of del(20q). Genes Chromosomes Cancer 2004;3:223–231.

47. Zojer N, Schuster-Kolbe J, Assmann I, et al. Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance. Br J Haematol 2002;117:852–859.

48. Maxwell CA, Keats JJ, Hendzel M, et al. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell 2003;14:2262–2276.

49. Pilarski LM, Adamia S, Maxwell CA, et al. Hyaluronan synthases and RHAMM as synergistic mediators of malignancy in B lineage cancers. In Balazcs EA, Hasclall VC, editors. Hyaluronan: Structure, Metabolism, Biological Activities, Therapeutic Applications, Chapter 4. Edgewater, NJ: Matrix Biology Institute; 2005. pp 329–338.